- Home
- NEO vs DYN Comparison
NEO vs DYN Comparison
Compare NEO & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEO
- DYN
- Stock Information
- Founded
- NEO 2001
- DYN 1984
- Country
- NEO United States
- DYN United States
- Employees
- NEO N/A
- DYN N/A
- Industry
- NEO Precision Instruments
- DYN Medicinal Chemicals and Botanical Products
- Sector
- NEO Health Care
- DYN Health Care
- Exchange
- NEO Nasdaq
- DYN Nasdaq
- Market Cap
- NEO 2.3B
- DYN 2.6B
- IPO Year
- NEO 1999
- DYN 2020
- Fundamental
- Price
- NEO $16.53
- DYN $23.99
- Analyst Decision
- NEO Strong Buy
- DYN Strong Buy
- Analyst Count
- NEO 10
- DYN 11
- Target Price
- NEO $20.30
- DYN $51.18
- AVG Volume (30 Days)
- NEO 756.1K
- DYN 891.4K
- Earning Date
- NEO 02-18-2025
- DYN 11-12-2024
- Dividend Yield
- NEO N/A
- DYN N/A
- EPS Growth
- NEO N/A
- DYN N/A
- EPS
- NEO N/A
- DYN N/A
- Revenue
- NEO $644,118,000.00
- DYN N/A
- Revenue This Year
- NEO $12.98
- DYN N/A
- Revenue Next Year
- NEO $9.83
- DYN N/A
- P/E Ratio
- NEO N/A
- DYN N/A
- Revenue Growth
- NEO 12.06
- DYN N/A
- 52 Week Low
- NEO $12.77
- DYN $12.06
- 52 Week High
- NEO $21.22
- DYN $47.45
- Technical
- Relative Strength Index (RSI)
- NEO 44.50
- DYN 32.86
- Support Level
- NEO $17.24
- DYN $25.08
- Resistance Level
- NEO $18.20
- DYN $26.69
- Average True Range (ATR)
- NEO 0.70
- DYN 1.48
- MACD
- NEO -0.28
- DYN -0.36
- Stochastic Oscillator
- NEO 6.41
- DYN 5.29
About NEO NeoGenomics Inc.
NeoGenomics Inc operates a network of cancer-focused genetic testing laboratories in the United States as well as a laboratory in Switzerland. The company operates into two segments namely Clinical Services and Advanced Diagnostics. It offers types of genetic and molecular testing services namely Cytogenetics, Fluorescence In-Situ Hybridization, Flow cytometry, Immunohistochemistry, Molecular testing, Pathology consultation. Advanced Diagnostics segment supports pharmaceutical firms in their drug development programs by supporting various clinical trials and research. For Clinical Services, Its specialized diagnostic services are performed based on an online test order or a written test requisition form. The company generates majority of its revenue from Clinical Services.
About DYN Dyne Therapeutics Inc.
Dyne Therapeutics Inc is a biotechnology company focused on providing therapeutics for patients with genetically driven diseases. The company overcomes the limitations of muscle tissue delivery and modern oligonucleotide therapeutics for muscle diseases. The company is developing therapies for muscle disorders like Myotonic dystrophy, Duchenne muscular dystrophy, and Facioscapulohumeral muscular dystrophy. The company's product candidates are DYNE-101 and DYNE-251, both are in the ongoing phase 1/2 clinical trial.